Key result
5-fluorouracil (5-FU) treatment resulted in a 1.6% overall incidence of cardiopathy, with a higher risk in patients with a history of previous cardiopathy.
Why the study?
What is the incidence of cardiotoxicity in patients receiving 5-fluorouracil chemotherapy for neoplasms?
Observational (n=1,083)
What is the incidence of cardiotoxicity in patients receiving 5-fluorouracil chemotherapy for neoplasms?
5-fluorouracil chemotherapy is associated with a 1.6% incidence of cardiotoxicity, which is significantly higher (4.5%) in patients with pre-existing cardiac disease.
Answers are grounded in this paper and cite their sources.
Supports pre-5-FU cardiac risk assessment; leaves open whether targeted monitoring alters outcomes.
The possible onset of cardiotoxic manifestations during chemotherapy with 5-fluorouracil (5-FU) was evaluated in 1083 patients treated with the drug for various kinds of neoplasm. We recognized 17 cases of 5-FU cardiopathy (usually anginous crises but also myocardial infarction). The comprehensive incidence was 1.6%, with a significantly greater risk (4.5% vs 1.1%) for patients with a positive anamnesis of previous cardiopathy. On the contrary, age and combination with other antiblastic drugs had no affect on the appearance of cardiopathy. We conclude that 5-FU cardiopathy, although rare, has to be taken into account in oncologic practice, chiefly in those patients already affected with cardiac diseases.
No takes yet. Share an insight, caveat, or question.
Labianca et al. (1982) conducted an observational in Neoplasm (n=1,083). 5-fluorouracil (5-FU) was evaluated on 5-FU cardiopathy (anginous crises or myocardial infarction). 5-fluorouracil (5-FU) treatment resulted in a 1.6% overall incidence of cardiopathy, with a higher risk in patients with a history of previous cardiopathy.
Synapse has enriched 10 related papers. Consider them for comparative context: